Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

S Chia, S Gandhi, AA Joy, S Edwards, M Gorr… - Current oncology, 2015 - mdpi.com
Abstract The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/Akt/mammalian target of
rapamycin) signalling pathway is an established driver of oncogenic activity in human …
被引用次数：125 相关文章
[PDF] semanticscholar.org

[PDF][PDF] Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer

S Chia, S Gandhi, AA Joy, S Edwards… - CURRENT …, 2015 - pdfs.semanticscholar.org
Discussion Everolimus likely represents the first of many complex oral targeted therapies for
the treatment of breast cancer. Using this agent as a template, it is essential to establish best …

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.

S Chia, S Gandhi, AA Joy, S Edwards… - Current Oncology …, 2015 - europepmc.org
Methods A comprehensive review of the literature conducted using a focused medline
search was combined with a search of current trials at http://ClinicalTrials. gov/. Summary …
[PDF] academia.edu

[PDF][PDF] Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer

S Chia, S Gandhi, AA Joy, S Edwards, M Gorr… - CURRENT …, 2015 - academia.edu
Discussion Everolimus likely represents the first of many complex oral targeted therapies for
the treatment of breast cancer. Using this agent as a template, it is essential to establish best …
[HTML] nih.gov

[HTML][HTML] Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

S Chia, S Gandhi, AA Joy, S Edwards, M Gorr… - Current …, 2015 - ncbi.nlm.nih.gov
The pi 3 k/Akt/m tor (phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin)
signalling pathway is an established driver of oncogenic activity in human malignancies …

Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

S Chia, S Gandhi, AA Joy, S Edwards, M Gorr… - Current …, 2015 - cir.nii.ac.jp
抄録< jats: p> The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/Akt/mammalian target of
rapamycin) signalling pathway is an established driver of oncogenic activity in human …

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

S Chia, S Gandhi, AA Joy… - Current oncology …, 2015 - pubmed.ncbi.nlm.nih.gov
The pi3k/Akt/mtor (phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin)
signalling pathway is an established driver of oncogenic activity in human malignancies …
[PDF] researchgate.net

[PDF][PDF] Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer

S Chia, S Gandhi, AA Joy, S Edwards… - CURRENT …, 2015 - researchgate.net
Discussion Everolimus likely represents the first of many complex oral targeted therapies for
the treatment of breast cancer. Using this agent as a template, it is essential to establish best …

Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer.

S Chia, S Gandhi, AA Joy, S Edwards… - Current …, 2015 - search.ebscohost.com
Abstract The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/Akt/mammalian target of
rapamycin) signalling pathway is an established driver of oncogenic activity in human …

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.

S Chia, S Gandhi, AA Joy, S Edwards… - Current Oncology …, 2015 - europepmc.org
Methods A comprehensive review of the literature conducted using a focused medline
search was combined with a search of current trials at http://ClinicalTrials. gov/. Summary …